Healthcare company Organon & Co. (OGN) said on Wednesday that it is discontinuing the development of its investigational ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

More than one quarter of the medcines cleared by the FDA’s main review office since 2015 have been cancer drugs, a tally that ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Endometriosis is more than just period pain, it’s a progressive disease that can damage vital organs, fertility, and mental ...

Organon (NYSE:OGN) stock is in focus as the company halts OG-6219 development after a Phase 2 trial in endometriosis-related pain fails. Read more here.

Suffering terribly with heavy periods for years, Liv was finally diagnosed with endometriosis. Now she wants more women like ...

The Global Endometriosis Treatment Market is expected to reach at a CAGR of 10.62% during the forecast period 2025-2033. Sai Kiran DataM Intelligence 4Market Research +1 877-441-4866 ... Visit us on ...

With nearly one third of women impacted by pelvic floor disorders, expanded care access and education from Progyny will help eliminate the silent sufferingNEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- ...